Transneural Therapeutics
Transneural Therapeutics focuses on creating neuroplastogens to treat challenging neuropsychiatric conditions. It uses an AI-assisted drug discovery platform combined with traditional medicinal chemistry to design small-molecule neuroplastogens aimed at improved efficacy and safety. The pipeline includes lead asset TN-001 and three additional programs, targeting CNS disorders such as Major Depressive Disorder and PTSD for patients and healthcare providers. The company operates in the biotechnology space with a drug development model, aiming to scale across neuropsychiatric indications.
Transneural Therapeutics
Transneural Therapeutics focuses on creating neuroplastogens to treat challenging neuropsychiatric conditions. It uses an AI-assisted drug discovery platform combined with traditional medicinal chemistry to design small-molecule neuroplastogens aimed at improved efficacy and safety. The pipeline includes lead asset TN-001 and three additional programs, targeting CNS disorders such as Major Depressive Disorder and PTSD for patients and healthcare providers. The company operates in the biotechnology space with a drug development model, aiming to scale across neuropsychiatric indications.